Alemtuzumab (anti-CD52), mogamulizumab (anti-CCR4), and zanolimumab (anti-CD4) have all been shown to induce a complete remission in a fraction of patients with relapse/refractory PTCL [3, 66, 67]. The gene discussed is CD52; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.